West Family Investments Inc. Makes New $236,000 Investment in GSK plc (NYSE:GSK)

West Family Investments Inc. acquired a new stake in shares of GSK plc (NYSE:GSK) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 5,780 shares of the pharmaceutical company’s stock, valued at approximately $236,000.

A number of other large investors also recently modified their holdings of GSK. 1832 Asset Management L.P. raised its holdings in GSK by 9.1% during the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock valued at $132,000 after acquiring an additional 257 shares during the period. Boltwood Capital Management lifted its holdings in shares of GSK by 2.5% in the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 270 shares in the last quarter. First Affirmative Financial Network boosted its holdings in shares of GSK by 4.7% during the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after purchasing an additional 283 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of GSK by 9.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 303 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. increased its holdings in shares of GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of NYSE:GSK opened at $33.46 on Wednesday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a market capitalization of $69.35 billion, a price-to-earnings ratio of 21.73, a PEG ratio of 1.28 and a beta of 0.66. The firm’s 50-day moving average is $38.66 and its 200 day moving average is $40.54.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a $0.3928 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. GSK’s dividend payout ratio is presently 99.35%.

Wall Street Analyst Weigh In

GSK has been the subject of a number of research reports. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Argus raised shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays raised GSK to a “hold” rating in a research note on Tuesday, August 27th. Seven investment analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and a consensus target price of $43.25.

Insider Buying and Selling

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of GSK stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.